Xiao Chai Hu Tang (Minor Bupleurum Decoction)

Actions

Indications

Western Uses:

• What conditions is Xiao Chai Hu Tang used for in modern practice?

  Xiao Chai Hu Tang harmonises a "half-exterior, half-interior" Shao-Yang disorder (alternating fever and chills, a bitter taste, fullness under the ribs, nausea and poor appetite), so it is referenced very broadly for these presentations: upper respiratory infections, influenza, bronchitis, pulmonary tuberculosis, mumps (epidemic parotitis), malaria, cholecystitis, hepatitis, jaundice, amenorrhoea, postpartum fever, lymphadenitis, and intercostal neuralgia.

  The thread is the Shao-Yang pattern, not any one diagnosis. Malaria is a life-threatening emergency, tuberculosis is a notifiable infection needing treatment, jaundice always requires assessment, and postpartum fever must be evaluated for infection. Traditional-use correlates only, not a treatment claim.

  Source: Sacred Lotus sources & references (pattern) + Bensky & Barolet, Formulas & Strategies; biomedical correlates as reference only. Not medical advice.

Originally Appeared In:

• On Cold Damage (Shang Han Lun)

Notes:

• How does Xiao Chai Hu Tang differ from other Chai Hu formulas, and where does it come from?

  Xiao Chai Hu Tang is the harmonizing archetype of the Chai Hu family; related formulas add or subtract herbs for a shifted pattern. It was first recorded in the Shang Han Lun (Treatise on Cold Damage) by Zhang Zhongjing, Eastern Han dynasty (compiled c. 200–220 CE), and also appears in the companion text Jin Gui Yao Lue (Essentials from the Golden Cabinet), attributed to the same author.

  • vs Da Chai Hu Tang (Major Bupleurum Decoction): shares the Chai Hu–Huang Qin base but drops the tonifying Ren Shen/Zhi Gan Cao and adds Da Huang and Zhi Shi, for a combined Shaoyang–Yangming excess pattern with constipation or more pronounced interior heat — a purging strategy rather than a harmonizing-with-tonification one.
  • vs Chai Hu Gui Zhi Tang: combines this formula (at reduced dosage) with Gui Zhi Tang, for simultaneous Taiyang (exterior) and Shaoyang involvement.
  • vs Si Ni San: both feature Chai Hu, but Si Ni San (Zhi Shi, Bai Shao, Zhi Gan Cao) treats Liver-Spleen qi stagnation without an external pathogen or Stomach-disharmony signs, and carries no anti-nausea or qi-tonifying herbs.

  A well-known classical principle associated with this formula in Shang Han Lun commentary is that presence of just one characteristic Shaoyang sign (e.g., alternating chills and fever, or chest-and-hypochondriac fullness) is sufficient grounds to use it — the complete symptom picture need not all be present at once.

  Documented classical modifications include removing Ban Xia and adding Tian Hua Fen (trichosanthes root) for pronounced thirst, and adding Fu Ling for palpitations with abdominal fullness.

  Source: Shang Han Lun (classical source text, secondary formulary commentary) + Bensky & Barolet, Formulas & Strategies; Chen & Chen, Chinese Medical Herbology and Pharmacology (comparative formula analysis, own words).

Clinical Studies & Research:

• Is there modern research on Xiao Chai Hu Tang, and what does the Japanese sho-saiko-to safety literature say?

  Yes on both counts: clinical research on efficacy exists, and a well-documented Japanese pharmacovigilance literature separately tracks interstitial pneumonitis associated with this same seven-herb combination. In Japan the formula is marketed as the Kampo medicine sho-saiko-to and has been one of the most-studied Kampo formulas for adverse-event reporting.

  • Peptic ulcer (clinical, efficacy): a systematic review and meta-analysis of 13 randomized controlled trials (1,334 patients) found Xiao Chai Hu Tang-based therapy associated with favorable clinical outcomes and fewer reported adverse effects versus conventional comparators for peptic ulcer disease (PMC 8105105).
  • Liver cirrhosis/hepatocellular carcinoma (clinical, efficacy and safety together): a review of sho-saiko-to in liver cirrhosis and carcinoma reported hepatoprotective associations while also flagging interstitial pneumonia as a known adverse effect, particularly when combined with interferon therapy (PMID 21682829).
  • Interstitial pneumonitis (safety literature, neutral reference — not a treatment claim): a review of 73 Japanese patients with herbal-medicine-induced pneumonitis identified sho-saiko-to as the most frequently implicated agent (PMID 28274529). An earlier case series documented five patients with sho-saiko-to-induced pneumonitis that resolved after discontinuation and corticosteroid treatment (PMID 9234626). Japan’s health authorities issued formal warnings on this association in the 1990s, and combination with interferon-alpha therapy is specifically flagged in the literature as raising risk.

  Sources: PMC 8105105 (peptic ulcer meta-analysis); PMID 21682829 (cirrhosis/carcinoma review); PMID 28274529 (Enomoto et al., pneumonitis review of 73 patients, Respiratory Investigation 2017); PMID 9234626 (Hatakeyama et al., five-case pneumonitis series, 1997). Research context and cited safety literature, not a therapeutic claim.